Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer

다국어 초록 (Multilingual Abstract)

Purpose The aim of the current study was to determine the incidence, clinical presentation, and treatment outcomes of “bone-only metastases” in patients with breast cancer and to analyze the impact of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2)status on prognosis.
Materials and Methods Between 1994 and 2007, of 968 patients with metastatic breast cancer who underwent palliative management at Samsung Medical Center, 565 (57%) relapsed with distant metastases. Of the 968, 146 (15%) had bone-only metastases during a median follow-up period of 75 months. Among the 146 patients with bone-only metastases, 122 (84%) were relapsed patients after curative surgery and 24 (26%) were initially metastatic cases.
Results The median time from primary surgery to bone-only metastases of the 122 patients was 37months (95% confidence interval [CI], 27 to 46 months). Bone-only metastases were more common in the HR-positive group than in the other subtypes (85% for HR+; 8.2% for HER2+;6.8%for triple negative. Among all 146 patients, 75 (51%) were treated with hormone therapy.
The median post-relapse progression-free survival was 15 months (95%CI, 13 to 17 months).
The median overall survival was much longer in the HR+ patients than the HER2+ and triple negative breast cancer patients with marginal statistical significance (65 vs. 40 vs. 40months, p=0.077).
Conclusion Breast cancer patients with “bone-only metastases” had excellent clinical outcomes.
Further study is now warranted to reveal the underlying biology that regulates the behavior of this indolent tumor, as it should identify ‘favorable tumor characteristics’ in addition to ‘favorable preferential metastatic site.’

참고문헌 (Reference)

1 Demicheli R, "Tumour dormancy: findings and hypotheses from clinical research on breast cancer" 11 : 297-306, 2001

2 Kamby C, "The pattern of metastases in human breast cancer: influence of systemic adjuvant therapy and impact on survival" 27 : 715-719, 1988

3 Bromann PA, "The interplay between Src family kinases and receptor tyrosine kinases" 23 : 7957-7968, 2004

4 Paget S, "The distribution of secondary growths in cancer of the breast" 133 : 571-573, 1889

5 Coleman RE, "The clinical course of bone metastases from breast cancer" 55 : 61-66, 1987

6 Pfitzenmaier J, "Telomerase activity in disseminated prostate cancer cells" 97 : 1309-1313, 2006

7 Smid M, "Subtypes of breast cancer show preferential site of relapse" 68 : 3108-3114, 2008

8 Coleman RE, "Skeletal complications of malignancy" 80 (80): 1588-1594, 1997

9 Lacroix M, "Significance, detection and markers of disseminated breast cancer cells" 13 : 1033-1067, 2006

10 Lee YT, "Patterns of metastasis and natural courses of breast carcinoma" 4 : 153-172, 1985

11 Chiang AC, "Molecular basis of metastasis" 359 : 2814-2823, 2008

12 Sherry MM, "Metastatic breast cancer confined to the skeletal system: an indolent disease" 81 : 381-386, 1986

13 Zhang XH, "Latent bone metastasis in breast cancer tied to Src-dependent survival signals" 16 : 67-78, 2009

14 Parkin DM, "Global cancer statistics" 49 : 33-64, 1999

15 Nguyen DX, "Genetic determinants of cancer metastasis" 8 : 341-352, 2007

16 Schmidt-Kittler O, "From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression" 100 : 7737-7742, 2003

17 Hess KR, "Estrogen receptors and distinct patterns of breast cancer relapse" 78 : 105-118, 2003

18 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), "Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials" 365 : 1687-1717, 2005

19 Karrison TG, "Dormancy of mammary carcinoma after mastectomy" 91 : 80-85, 1999

20 Weckermann D, "Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value" 166 : 699-703, 2001

21 Coleman RE, "Clinical course and prognostic factors following bone recurrence from breast cancer" 77 : 336-340, 1998

22 Carlson RW, "Breast cancer: clinical practice guidelines in oncology" 7 : 122-192, 2009

23 Sherry MM, "Breast cancer with skeletal metastases at initial diagnosis. Distinctive clinical characteristics and favorable prognosis" 58 : 178-182, 1986